AU2005266887B2 - Method of diagnosing, monitoring and treating pulmonary diseases - Google Patents

Method of diagnosing, monitoring and treating pulmonary diseases Download PDF

Info

Publication number
AU2005266887B2
AU2005266887B2 AU2005266887A AU2005266887A AU2005266887B2 AU 2005266887 B2 AU2005266887 B2 AU 2005266887B2 AU 2005266887 A AU2005266887 A AU 2005266887A AU 2005266887 A AU2005266887 A AU 2005266887A AU 2005266887 B2 AU2005266887 B2 AU 2005266887B2
Authority
AU
Australia
Prior art keywords
lung function
compound
difference
subject
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005266887A
Other languages
English (en)
Other versions
AU2005266887A1 (en
Inventor
Peter J. Barnes
Sergei A. Kharitonov
Amir Pelleg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
DUSKA SCIENT CO
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DUSKA SCIENT CO, Duska Scientific Co filed Critical DUSKA SCIENT CO
Publication of AU2005266887A1 publication Critical patent/AU2005266887A1/en
Application granted granted Critical
Publication of AU2005266887B2 publication Critical patent/AU2005266887B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2005266887A 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases Ceased AU2005266887B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59010104P 2004-07-22 2004-07-22
US60/590,101 2004-07-22
US66203305P 2005-03-15 2005-03-15
US60/662,033 2005-03-15
PCT/US2005/026884 WO2006012639A2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Publications (2)

Publication Number Publication Date
AU2005266887A1 AU2005266887A1 (en) 2006-02-02
AU2005266887B2 true AU2005266887B2 (en) 2011-08-18

Family

ID=35786780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005266887A Ceased AU2005266887B2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Country Status (6)

Country Link
US (2) US20060029548A1 (enExample)
EP (1) EP1773405A4 (enExample)
JP (1) JP2008507368A (enExample)
AU (1) AU2005266887B2 (enExample)
CA (1) CA2573565A1 (enExample)
WO (1) WO2006012639A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620034C (en) * 2005-09-01 2013-10-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
KR101422901B1 (ko) 2009-02-13 2014-07-23 시오노기 앤드 컴파니, 리미티드 신규 트라이아진 유도체 및 그것을 함유하는 의약 조성물
US20100222294A1 (en) * 2009-02-27 2010-09-02 Duska Scientific Co. Formulations of ATP and Analogs of ATP
EP2432422A4 (en) 2009-05-18 2018-01-17 PneumRx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
US20130164386A1 (en) * 2010-06-17 2013-06-27 The Johns Hopkins University Targeting the Alpha3 Subnit of Na+-K+-ATPase for the Treatment of Cough with Sulfenamides
EP2604595B1 (en) 2010-08-10 2016-03-16 Shionogi&Co., Ltd. Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
JP6138044B2 (ja) * 2011-08-10 2017-05-31 国立大学法人富山大学 痺れ又は自発痛の評価方法及び薬物のスクリーニング方法
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
JP6546592B2 (ja) * 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
WO2015061790A2 (en) 2013-10-25 2015-04-30 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US11622716B2 (en) 2017-02-13 2023-04-11 Health Care Originals, Inc. Wearable physiological monitoring systems and methods
US11272864B2 (en) 2015-09-14 2022-03-15 Health Care Originals, Inc. Respiratory disease monitoring wearable apparatus
HUE061764T2 (hu) 2015-09-29 2023-08-28 Afferent Pharmaceuticals Inc Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében
US11241579B2 (en) * 2016-04-22 2022-02-08 The Regents Of The University Of California Monitoring and modulation of parasympathetic nervous system
US10955269B2 (en) 2016-05-20 2021-03-23 Health Care Originals, Inc. Wearable apparatus
US20210278418A1 (en) * 2018-03-15 2021-09-09 The Chidlren's Medical Center Corporation Method for treating asthma or allergic disease
PL3862000T3 (pl) 2018-10-05 2024-03-18 Shionogi & Co., Ltd Lek na przewlekły kaszel
MX2022002941A (es) 2019-09-19 2022-04-06 Shionogi & Co Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122466A (en) * 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
JP3121827B2 (ja) * 1990-09-04 2001-01-09 メドコ・リサーチ・インコーポレイテッド アデノシンまたはそのリン酸化誘導体を活性成分とする気管支収縮性肺疾患の診断剤
GB9109063D0 (en) * 1991-04-26 1991-06-12 Ici Plc Modification of lignin synthesis in plants
US5527586A (en) * 1992-03-18 1996-06-18 Printron, Inc. Apparatus and method for depositing metal particles on a dielectric substrate
US5348616A (en) * 1993-05-03 1994-09-20 Motorola, Inc. Method for patterning a mold
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5597613A (en) * 1994-12-30 1997-01-28 Honeywell Inc. Scale-up process for replicating large area diffractive optical elements
US6309580B1 (en) * 1995-11-15 2001-10-30 Regents Of The University Of Minnesota Release surfaces, particularly for use in nanoimprint lithography
US6482742B1 (en) * 2000-07-18 2002-11-19 Stephen Y. Chou Fluid pressure imprint lithography
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US6204434B1 (en) * 1996-09-11 2001-03-20 Genesis Research & Development Corporation Limited Materials and methods for the modification of plant lignin content
US6653528B1 (en) * 1996-09-11 2003-11-25 Genesis Research & Development Corporation Limited Pinus radiata nucleic acids encoding O-methyl transferase and methods for the modification of plant lignin content therewith
US6410718B1 (en) * 1996-09-11 2002-06-25 Genesis Research & Development Corporation Ltd. Materials and methods for the modification of plant lignin content
US5850020A (en) * 1996-09-11 1998-12-15 Genesis Research & Development Corporation, Ltd. Materials and method for the modification of plant lignin content
US5735985A (en) * 1996-11-15 1998-04-07 Eastman Kodak Company Method for micromolding ceramic structures
JP2001518118A (ja) * 1997-03-25 2001-10-09 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ ヒト肥満細胞活性化のモジュレーション
US6225143B1 (en) * 1998-06-03 2001-05-01 Lsi Logic Corporation Flip-chip integrated circuit routing to I/O devices
US6110401A (en) * 1998-08-24 2000-08-29 Physical Optics Corporation Method and apparatus for replicating light shaping surface structures on a rigid substrate
US6190929B1 (en) * 1999-07-23 2001-02-20 Micron Technology, Inc. Methods of forming semiconductor devices and methods of forming field emission displays
US6517995B1 (en) * 1999-09-14 2003-02-11 Massachusetts Institute Of Technology Fabrication of finely featured devices by liquid embossing
DE60127098T2 (de) * 2000-01-31 2007-11-29 Genaera Corp. Inhibitoren der mucin-synthese
US6387787B1 (en) * 2001-03-02 2002-05-14 Motorola, Inc. Lithographic template and method of formation and use
DE60206164T2 (de) * 2001-05-18 2006-06-22 Abbott Laboratories, Abbott Park Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
US6716754B2 (en) * 2002-03-12 2004-04-06 Micron Technology, Inc. Methods of forming patterns and molds for semiconductor constructions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRIE, G.P. ET AL, Journal of Asthma. 2004, vol. 41, no. 3, pages 247-258 *
PELEG, A. & SCHULMAN, E.S., American Journal of Therapeutics. 2002, vol. 9, no. 5, pages 454-464 *
RUTGERS, S.R. ET AL., European Respiratory Journal. 2000, vol. 16, no. 3, pages 486-490 *

Also Published As

Publication number Publication date
CA2573565A1 (en) 2006-02-02
EP1773405A2 (en) 2007-04-18
WO2006012639A9 (en) 2006-03-16
WO2006012639A2 (en) 2006-02-02
WO2006012639A3 (en) 2006-06-22
US20100286274A1 (en) 2010-11-11
US20060029548A1 (en) 2006-02-09
JP2008507368A (ja) 2008-03-13
AU2005266887A1 (en) 2006-02-02
EP1773405A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
AU2005266887B2 (en) Method of diagnosing, monitoring and treating pulmonary diseases
Moskowitz et al. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms
Krishna et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma
Bonvini et al. Targeting TRP channels for chronic cough: from bench to bedside
Cerrina et al. Comparison of human bronchial muscle responses to histamine in vivo with histamine and isoproterenol agonists in vitro
Basoglu et al. Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD
Taylor et al. Airway reactivity in chronic obstructive pulmonary disease: failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro
Szczeklik et al. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma.
Garthwaite et al. Synaptic activation of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors in the mossy fibre pathway in adult and immature rat cerebellar slices
Komai et al. Acetazolamide specifically inhibits lingual trigeminal nerve responses to carbon dioxide
Schmidt et al. Adenosinergic modulation of respiratory neurones and hypoxic responses in the anaesthetized cat.
Benson et al. Bronchial reactivity: interaction between vagal stimulation and inhaled histamine
Fujimura et al. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis
Ruffin et al. A comparison of the protective effect of fenoterol and Sch1000 on allergen-induced asthma
Tung et al. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids
Chung Review series: chronic cough: future directions in chronic cough: mechanisms and antitussives
Enarson et al. Predictors of bronchial hyperexcitability in grainhandlers
Dong et al. Sensitivity of rat temporalis muscle afferent fibers to peripheral N-methyl-D-aspartate receptor activation
Penn et al. Effects of inflammation and acute beta-agonist inhalation on beta 2-AR signaling in human airways
Inoue et al. Excitatory role of axon reflex in bradykinin-induced contraction of guinea pig tracheal smooth muscle
Wilson et al. Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets
Morr Immunological release of histamine from human lung: II. Studies on acetylcholine and the anticholinergic agent ipratropium bromide
Leader et al. Symptomatology, Pulmonary Function and Response, and T Lymphocyte β2‐Receptors During Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease
Zhang et al. Prostaglandin E2 enhances the sensitizing effect of hyperthermia on pulmonary C-fibers in rats
Ioka et al. Natural killer activity and its changes among participants in a smoking cessation intervention program-a prospective pilot study of 6 months' duration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired